Pyruvate Kinase M2: a Metabolic Bug in Re-Wiring the Tumor Microenvironment - PubMed
Review
Pyruvate Kinase M2: a Metabolic Bug in Re-Wiring the Tumor Microenvironment
Mohd Rihan et al. Cancer Microenviron. 2019 Dec.
Abstract
Metabolic reprogramming is a newly emerged hallmark of cancer attaining a recent consideration as an essential factor for the progression and endurance of cancer cells. A prime event of this altered metabolism is increased glucose uptake and discharge of lactate into the cells surrounding constructing a favorable tumor niche. Several oncogenic factors help in promoting this consequence including, pyruvate kinase M2 (PKM2) a rate-limiting enzyme of glycolysis in tumor metabolism via exhibiting its low pyruvate kinase activity and nuclear moon-lightening functions to increase the synthesis of lactate and macromolecules for tumor proliferation. Not only its role in cancer cells but also its role in the tumor microenvironment cells has to be understood for developing the small molecules against it which is lacking with the literature till date. Therefore, in this present review, the role of PKM2 with respect to various tumor niche cells will be clarified. Further, it highlights the updated list of therapeutics targeting PKM2 pre-clinically and clinically with their added limitations. This upgraded understanding of PKM2 may provide a pace for the reader in developing chemotherapeutic strategies for better clinical survival with limited resistance.
Keywords: Aerobic glycolysis; Metabolic reprogramming; PKM2; Tumor metabolism; Tumor microenvironment.
Conflict of interest statement
The authors declare no conflict of interest.
Figures

Aerobic glycolysis in cancer cells: Illustration represents that cancer cells undergo aerobic glycolysis by inflowing the glucose molecules and converts the produced pyruvate to lactate instead of allowing it to enter TCA cycle in the aerobic conditions. Oncogenic proteins involved with the tumorigenesis upregulate many enzymes and transporters (indicated by *) of glycolysis further supporting this process

Components of tumor microenvironment: Illustration represents the cellular and non-cellular composition of the tumor microenvironment

Regulation of TME cells in the tumor microenvironment: Illustration represents the regulatory molecules modulated by PKM2 in different TME cells. This modulation helps in their activation and progression
Similar articles
-
Pyruvate kinase M2 (PKM2) in cancer and cancer therapeutics.
Zhu S, Guo Y, Zhang X, Liu H, Yin M, Chen X, Peng C. Zhu S, et al. Cancer Lett. 2021 Apr 10;503:240-248. doi: 10.1016/j.canlet.2020.11.018. Epub 2020 Nov 24. Cancer Lett. 2021. PMID: 33246091 Review.
-
Pyruvate Kinase M2 and Cancer: The Role of PKM2 in Promoting Tumorigenesis.
Zahra K, Dey T, Ashish, Mishra SP, Pandey U. Zahra K, et al. Front Oncol. 2020 Mar 2;10:159. doi: 10.3389/fonc.2020.00159. eCollection 2020. Front Oncol. 2020. PMID: 32195169 Free PMC article. Review.
-
Li S, Ji X, Wang R, Miao Y. Li S, et al. Arch Gynecol Obstet. 2019 May;299(5):1443-1451. doi: 10.1007/s00404-019-05100-4. Epub 2019 Feb 26. Arch Gynecol Obstet. 2019. PMID: 30809696
-
Guo J, Xue Q, Liu K, Ge W, Liu W, Wang J, Zhang M, Li QY, Cai D, Shan C, Zhang C, Liu X, Li J. Guo J, et al. Front Oncol. 2019 Oct 2;9:993. doi: 10.3389/fonc.2019.00993. eCollection 2019. Front Oncol. 2019. PMID: 31632919 Free PMC article.
-
Revisited Metabolic Control and Reprogramming Cancers by Means of the Warburg Effect in Tumor Cells.
Fukushi A, Kim HD, Chang YC, Kim CH. Fukushi A, et al. Int J Mol Sci. 2022 Sep 2;23(17):10037. doi: 10.3390/ijms231710037. Int J Mol Sci. 2022. PMID: 36077431 Free PMC article. Review.
Cited by
-
Pralea IE, Petrache AM, Tigu AB, Gulei D, Moldovan RC, Ilieș M, Nicoară R, Hegheș SC, Uifălean A, Iuga CA. Pralea IE, et al. Pharmaceuticals (Basel). 2022 Jun 28;15(7):808. doi: 10.3390/ph15070808. Pharmaceuticals (Basel). 2022. PMID: 35890106 Free PMC article. Review.
-
Xu N, Wu K, La T, Cao B. Xu N, et al. Heliyon. 2024 Aug 2;10(15):e35617. doi: 10.1016/j.heliyon.2024.e35617. eCollection 2024 Aug 15. Heliyon. 2024. PMID: 39170262 Free PMC article.
-
Yi Z, Wu Y, Zhang W, Wang T, Gong J, Cheng Y, Miao C. Yi Z, et al. Front Immunol. 2021 Jan 19;11:595316. doi: 10.3389/fimmu.2020.595316. eCollection 2020. Front Immunol. 2021. PMID: 33542713 Free PMC article.
-
Gu J, Li X, Zhao L, Yang Y, Xue C, Gao Y, Li J, Han Q, Sun Z, Bai C, Zhao RC. Gu J, et al. Cell Death Dis. 2021 Mar 17;12(4):291. doi: 10.1038/s41419-021-03579-x. Cell Death Dis. 2021. PMID: 33731686 Free PMC article.
-
Yu Q, Guo M, Zeng W, Zeng M, Zhang X, Zhang Y, Zhang W, Jiang X, Yu B. Yu Q, et al. Immun Inflamm Dis. 2022 Mar;10(3):e581. doi: 10.1002/iid3.581. Epub 2021 Dec 13. Immun Inflamm Dis. 2022. PMID: 34904398 Free PMC article. Review.
References
-
- Siegel Rebecca L., Miller Kimberly D., Jemal Ahmedin. Cancer statistics, 2018. CA: A Cancer Journal for Clinicians. 2018;68(1):7–30. - PubMed
-
- Seth S, Li C-Y, Ho I-L, Corti D, Loponte S, Sapio L, Del Poggetto E, Yen E-Y, Robinson FS, Peoples M. Pre-existing Functional Heterogeneity of Tumorigenic Compartment as the Origin of Chemoresistance in Pancreatic Tumors. Cell Rep. 2019;26(6):1518–1532. e1519. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous